Crossmark

Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis

Published Online: 2022-06-16

Published Print: 2022-12

Authors

Hector, Emma

Cairns, Donald

Michael Wall, G. https://orcid.org/0000-0002-4928-9488
Funding

Funding for this research was provided by:

Nacuity Pharmaceuticals, Inc.
License Information

Text and Data Mining valid from 2022-06-16

Version of Record valid from 2022-06-16
More Information

Article History

Received: 1 March 2022

Accepted: 13 May 2022

First Online: 16 June 2022

Declarations

:

: Not applicable.

: Not applicable.

: GMW is an employee and stockholder of Nacuity Pharmaceuticals, Inc. EH and DC are independent academic investigators with no conflicts.

Document is current